Drug Discovery

#Biotherapeutics #Drug development #Immunology / Virology & Vaccines #Vaccines

ENPICOM accelerates antibody and vaccine discovery

Viroclinics-DDL, a Contract Research Organisation (CRO) specialising in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines in vitro diagnostic and high-throughput sequencing… Read More

#News

#Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Vaccines

GSK to support manufacture of Novavax’ Covid-19 vaccine

Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ Covid-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide… Read More

#Covid-19 #News

#Covid-19 #Drug development #Immunology / Virology & Vaccines #Research

Modelling and simulation facilitates drug repurposing to counter Covid-19

By Dr Craig R. Rayner, FRCP Edin, PharmD, MBA, President, Integrated Drug Development at Certara Right at the start of the Covid-19 pandemic, medical researchers began questioning whether there were any existing, on-market drugs that might prove effective against SARS-CoV-2. They wanted to offer healthcare professionals and patients some known… Read More

#Business & Investment #Exclusive Content #News

#Dementia #Drug development #Drug discovery #Muscles #Research

Scientists study how signals from muscles can protect from dementia

Scientists at St. Jude Children’s Research Hospital are studying how signals sent from skeletal muscle affect the brain. The team studied fruit flies and brain cell models called organoids, focusing on the signals that muscles send when stressed. They used immunostaining and confocal microscopy on the fruit fly brain and… Read More

#News

#Awards #Cell therapy #Drug development #Therapeutics

Mogrify wins awards for innovation and named business of the year

Mogrify, a UK company which aims to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards 2020. Read More

#News

#Biotechnology #Biotherapeutics #Drug development #Drug discovery #Therapeutics

1910 Genetics launches to accelerate therapeutics design

Biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, has launched after closing its $22 million Series A funding round. 1910 Genetics’ aim is to decrease the timeline and cost of drug development, while improving the success rate of getting medicines to patients. 1910 Genetics… Read More

#News

#Biotherapeutics #Coronavirus #Covid-19 #Drug development

Infex filed for UK patent for coronavirus novel therapy design

Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all coronavirus strains. The COV-X program targets a protein which is essential for viral replication across a broad spectrum of related coronaviruses, including SARS-CoV-1, MERS-CoV and SARS-CoV-2. If successfully developed, the treatment aims to form… Read More

#Covid-19 #News

#Drug design #Drug development #Drug discovery #Neuroscience #Parkinson's

IRICoR and Valence collaborate in AI drug design for Parkinson’s

IRICoR, a pan-Canadian drug discovery and research commercialisation centre, Université de Montréal (UdeM), the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Valence Discovery, an emerging leader in AI-enabled drug design, have announced a collaboration focused on the discovery of novel drug candidates for… Read More

#News

#Drug delivery #Drug development #Drug discovery #Research

Russian scientists’ to help create targeted drug delivery capsules

Scientists from MIPT and ITMO University and their colleagues have studied the formation and growth of crystals from simple organic molecules into large associations, which may help create capsules for targeted drug delivery to specific tissues in the human body. The scientific paper was published in the journal Crystal Growth… Read More

#News

#Clinical trials #Covid-19 #Drug development #Drug discovery #Research

Hormone drugs may disarm COVID-19 spike protein

Researchers in the Abramson Cancer Center at the University of Pennsylvania have published a new preclinical study which found hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease. The study, published online in Cell Press’s iScience, showed how two… Read More

#Covid-19 #News

#Drug candidates #Drug delivery #Drug development #Drug discovery #Gene therapy

Ilya’s ILP100 gene therapy speeds up healing by six days on average

Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial #Data #Drug development #Drug discovery #Report

Report promotes the use of synthetic data in clinical trials

Phesi, provider of AI-powered clinical development analytics products and solutions, and Accenture, a services and consulting company, have released the first of a series of reports exploring the use of synthetic data in clinical development. In recent years, the volume of data created through clinical trials and electronic patient records… Read More

#News

#Antibodies #Biologics #Covid-19 #Drug development #Drug discovery #Online focus

IONTAS has identified novel SARS-CoV-2 neutralising antibodies

IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More

#News

#Biotechnology #Covid-19 #Drug development

Molecular ‘cookie cutter’ method could provide key for COVID drug discovery

Researchers from the University of Birmingham are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future anti-viral drugs. The encounter complex is formed when the COVID-19 spike latches onto a binding site on an ACE-2 receptor,… Read More

#News

#Biopharmaceuticals #Drug development #Drug discovery #Oncology

LDC and Cumulus Oncology announce collaboration

The Lead Discovery Centre (LDC) and Cumulus Oncology are collaborating to enable the two organisations to accelerate the discovery and development of novel oncology therapies. LDC contributes drug discovery expertise and a team of scientists with the ability to develop assets modulating a range of oncology targets derived from its… Read More

#News